NCT07311330

Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

A Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Beijing Inno Medicine Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of YN001 in patients with atherosclerotic cardiovascular and cerebrovascular diseases and erectile dysfunction

Conditions

• Atherosclerotic Cardiovascular Disease (ASCVD)
• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	YN001 20mg Dose + 5% glucose injection	The treamtment group was given YN001 20 mg, once a week (QW), cumulative administration for 12 weeks (about 3 months)
OTHER	5% glucose injection	The control group was given placebo once a week (QW), cumulative administration for 12 weeks (about 3 months)

Timeline

• Start date: 2026-01-31
• Primary completion: 2026-06-16
• Completion: 2026-11-14
• First posted: 2025-12-30
• Last updated: 2025-12-30